 Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 9 | 9 | | 1996 | 0 | 7 | 7 | | 1997 | 0 | 7 | 7 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 7 | 7 | | 2000 | 0 | 7 | 7 | | 2001 | 0 | 8 | 8 | | 2002 | 0 | 14 | 14 | | 2003 | 0 | 13 | 13 | | 2004 | 0 | 17 | 17 | | 2005 | 0 | 17 | 17 | | 2006 | 1 | 22 | 23 | | 2007 | 0 | 33 | 33 | | 2008 | 0 | 25 | 25 | | 2009 | 0 | 26 | 26 | | 2010 | 0 | 28 | 28 | | 2011 | 0 | 29 | 29 | | 2012 | 0 | 27 | 27 | | 2013 | 0 | 24 | 24 | | 2014 | 0 | 33 | 33 | | 2015 | 0 | 30 | 30 | | 2016 | 0 | 25 | 25 | | 2017 | 0 | 35 | 35 | | 2018 | 2 | 32 | 34 | | 2019 | 0 | 28 | 28 | | 2020 | 0 | 14 | 14 | | 2021 | 1 | 15 | 16 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 8 | 8 | | 2025 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24; 392(16):1569-1581.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Vel?squez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875.
-
Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Burnett P, Chu DH, Almaraz E, Higham RC, Berk DR. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5?Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. Pediatr Dermatol. 2025 Mar-Apr; 42(2):296-304.
-
Piccolo R, Simonetti F, Avvedimento M, Cutillo M, Canonico ME, Conti V, Gargiulo G, Paolillo R, Dal Piaz F, Filippelli A, Charlier B, Spinelli A, Cristiano S, Cirillo P, Di Serafino L, Franzone A, Esposito G. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur Heart J Cardiovasc Pharmacother. 2024 Nov 06; 10(7):578-587.
-
Goldenberg NA, Schulman S, Kittelson JM, Abshire TC, Casella JF, Dale R, Halperin JL, Hanson J, Kessler CM, Manco-Johnson MJ, McDevitt L, Sidonio RF, Spyropoulos AC, Steg PG, Bonaca MP. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. J Thromb Haemost. 2025 Feb; 23(2):651-656.
-
Morales J, King A, Oser S, D'Souza S. Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes. Postgrad Med. 2024 Nov; 136(8):791-800.
-
Katz SE, Jenkins TC, Stein AB, Thomas G, Koenig N, Starnes GL, Newland JG, Banerjee R, Frost HM. Durations of Antibiotic Treatment for Acute Otitis Media and Variability in Prescribed Durations Across Two Large Academic Health Systems. J Pediatric Infect Dis Soc. 2024 Sep 26; 13(9):455-465.
-
Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S, Kimura T, Lopes RD, Mehta SR, Montalescot G, Sibbing D, Steg PG, Stone GW, Storey RF, Vranckx P, Windecker S, Mehran R. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23; 150(4):317-335.
-
El Feghaly RE, Jaggi P, Katz SE, Poole NM. "Give Me Five": The Case for 5 Days of Antibiotics as the Default Duration for Acute Respiratory Tract Infections. J Pediatric Infect Dis Soc. 2024 Jun 28; 13(6):328-333.
-
Kienzle MF, Morgan RW, Reeder RW, Ahmed T, Berg RA, Bishop R, Bochkoris M, Carcillo JA, Carpenter TC, Cooper KK, Diddle JW, Federman M, Fernandez R, Franzon D, Frazier AH, Friess SH, Frizzola M, Graham K, Hall M, Horvat C, Huard LL, Maa T, Manga A, McQuillen PS, Meert KL, Mourani PM, Nadkarni VM, Naim MY, Pollack MM, Sapru A, Schneiter C, Sharron MP, Tabbutt S, Viteri S, Wolfe HA, Sutton RM. Epinephrine Dosing Intervals Are Associated With Pediatric In-Hospital Cardiac Arrest Outcomes: A Multicenter Study. Crit Care Med. 2024 Sep 01; 52(9):1344-1355.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|